Here is the design of a clinical trial:

Official Title: Tranexamic Acid During Cystectomy Trial (TACT)

Included conditions:
- Bladder Cancer

Study Armgroups:
- {'label': 'Tranexamic Acid', 'type': 'EXPERIMENTAL', 'description': 'Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.', 'interventionNames': ['Drug: Tranexamic Acid']}
- {'label': 'Placebo control', 'type': 'PLACEBO_COMPARATOR', 'description': 'As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Tranexamic Acid', 'description': 'Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).', 'armGroupLabels': ['Tranexamic Acid'], 'otherNames': ['Cyklokapron (Pfizer)']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.', 'armGroupLabels': ['Placebo control'], 'otherNames': ['Normal Saline']}

Primary Outcomes:
- {'measure': 'proportion of patients transfused at least one unit of packed red blood cell transfusion', 'timeFrame': 'up to 30 days post-operative'}

Please estimate the sample size based on the assumption: 
Assuming 80% power to detect a 15% absolute difference, with a two-sided alpha level of 5%, and accounting for 2% non-compliance.
Sample size
        A patient record review from The Ottawa Hospital indicated that red blood cell transfusions were performed in approximately 60% of patients with bladder cancer undergoing radical cystectomy. However, we anticipate that transfusion rates are likely to decrease slightly while under the study protocol. From the results of our survey, systemic anti-fibrinolytics are rarely used during radical cystectomies; to influence practice we suggest that tranexamic acid will have to produce a substantial reduction in the proportion of patients requiring transfusion. To assist in determining the minimally important effect of tranexamic acid deemed necessary to change clinical practice, Canadian experts in the surgical treatment of bladder cancer were surveyed in February 2012. Minimally important effect sizes ranged from an absolute difference of 15% (relative risk (RR) 30%) to 30% (RR 60%) and are consistent with effects observed in many clinical trials of tranexamic acid [12]. From our systematic review of lysine analogs to prevent bleeding during pelvic surgery, the pooled estimate favored lysine analogs (RR 0.69; 95% confidence interval (CI) 0.47 to 1.00) [13].
        If 50% of placebo patients will require at least one transfusion within 30Â days of surgery, and if the use of tranexamic acid reduces the need for transfusion within 30Â days to 35% of patients (15% absolute reduction), and assuming 80% power to detect this absolute difference, with a two-sided alpha level of 5%, the required sample size is 340 people (170 per treatment group). To account for 2% non-compliance with the protocol (possibly due to intraoperative complications or protocol deviations) the total sample size required was estimated to be 354 patients (177 per arm) [15].